DrugPatentWatch Database Preview

Details for Patent: 10,028,925

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,028,925 protect, and when does it expire?

Patent 10,028,925 protects NAPROXEN SODIUM and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 10,028,925

Title:	Liquid dosage forms of sodium naproxen
Abstract:	Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
Inventor(s):	Chidambaram; Nachiappan (Sandy, UT), Fatmi; Aqeel A (High Point, NC)
Assignee:	Patheon Softgels, Inc. (High Point, NC)
Application Number:	15/591,512
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,028,925
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,028,925

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bionpharma Inc	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006		OTC	Yes	Yes			Y			TEMPORARY RELIEF OF MINOR ACHES AND PAINS
Bionpharma Inc	NAPROXEN SODIUM	naproxen sodium	CAPSULE;ORAL	021920-001	Feb 17, 2006		OTC	Yes	Yes			Y			TEMPORARY REDUCTION OF FEVER

International Family Members for US Patent 10,028,925

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2600023
China	101166520
China	102940887
Cyprus	1118321
Denmark	1863458
European Patent Office	1863458